AR064500A1 - Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas - Google Patents

Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas

Info

Publication number
AR064500A1
AR064500A1 ARP070105865A ARP070105865A AR064500A1 AR 064500 A1 AR064500 A1 AR 064500A1 AR P070105865 A ARP070105865 A AR P070105865A AR P070105865 A ARP070105865 A AR P070105865A AR 064500 A1 AR064500 A1 AR 064500A1
Authority
AR
Argentina
Prior art keywords
plants
wnv
vectors
west nile
nile virus
Prior art date
Application number
ARP070105865A
Other languages
English (en)
Spanish (es)
Original Assignee
Dow Agrosciences Llc
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc, Us Agriculture filed Critical Dow Agrosciences Llc
Publication of AR064500A1 publication Critical patent/AR064500A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP070105865A 2006-12-22 2007-12-21 Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas AR064500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87151806P 2006-12-22 2006-12-22

Publications (1)

Publication Number Publication Date
AR064500A1 true AR064500A1 (es) 2009-04-08

Family

ID=40032322

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105865A AR064500A1 (es) 2006-12-22 2007-12-21 Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas

Country Status (8)

Country Link
US (1) US7888069B2 (enExample)
EP (1) EP2099916A2 (enExample)
JP (1) JP2010514698A (enExample)
AR (1) AR064500A1 (enExample)
AU (1) AU2007353773A1 (enExample)
BR (1) BRPI0721141A2 (enExample)
CA (1) CA2671934A1 (enExample)
WO (1) WO2008143713A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439264B1 (en) 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
WO2012095874A1 (en) 2011-01-11 2012-07-19 Enneffe S.R.L. Adjustable anti -theft device
WO2013191997A1 (en) * 2012-06-18 2013-12-27 Dow Agrosciences Llc Expression of maize codon optimized proteins in pseudomonas fluorescens
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
US12430678B2 (en) * 2022-12-16 2025-09-30 Sap Se Solving sparse data problems in a recommendation system with freezing start
US12443985B2 (en) 2022-12-16 2025-10-14 Sap Se Solving sparse data problems in a recommendation system with cold start

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US5637489A (en) 1986-08-23 1997-06-10 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5276268A (en) 1986-08-23 1994-01-04 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5273894A (en) 1986-08-23 1993-12-28 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991009957A1 (en) 1989-12-22 1991-07-11 E.I. Du Pont De Nemours And Company Site-specific recombination of dna in plant cells
US5183740A (en) 1990-02-23 1993-02-02 The United States Of America As Represented By The Secretary Of The Navy Flow immunosensor method and apparatus
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
TW261517B (enExample) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
AU4382193A (en) 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
DE69331908T2 (de) 1992-10-05 2002-12-12 North Carolina State University, Raleigh Verfahren zur erhöhung der expression und zur verminderung der expressionsvariabilität von fremdgenen in pflanzenzellen
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US5753439A (en) 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5750352A (en) 1995-08-23 1998-05-12 The Johns Hopkins University Mono-allelic mutation analysis for identifying germline mutations
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
US6214545B1 (en) 1997-05-05 2001-04-10 Third Wave Technologies, Inc Polymorphism analysis by nucleic acid structure probing
ATE231917T1 (de) 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
US6319691B1 (en) 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US6342362B1 (en) 1999-08-05 2002-01-29 Daniel S. Mytelka Methods and compositions for the purification of proteins or other macromolecules
AU2003290985B2 (en) * 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
NZ542933A (en) 2003-05-05 2009-08-28 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
EP1626708B1 (en) * 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
US20080034455A1 (en) * 2004-05-21 2008-02-07 Simon Fraser University Production Of A Protein Localized To The Endoplasmic Reticulum Protein Bodies In A Transgenic Plant And Seed

Also Published As

Publication number Publication date
BRPI0721141A2 (pt) 2014-04-01
WO2008143713A2 (en) 2008-11-27
JP2010514698A (ja) 2010-05-06
CA2671934A1 (en) 2008-11-27
EP2099916A2 (en) 2009-09-16
WO2008143713A3 (en) 2009-03-12
US20090069229A1 (en) 2009-03-12
AU2007353773A1 (en) 2008-11-27
US7888069B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
NI201200080A (es) Antagonistas de il-17a
CO7121348A2 (es) Proteínas de fusión de interleuquina-2 y usos de las mismas
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
AR078778A1 (es) Proteinas de union a antigenos de il-23
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
MX393869B (es) Polinucleotidos que codifican interleucina-12 (il12) y usos de los mismos.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
BR112018072282A2 (pt) composições detergentes e usos das mesmas
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
CL2012003655A1 (es) Uso de proteina alfa-n-acetilglucosaminidasa (naglu) recombinante para tratar sindrome de sanfilippo tipo b (san b); proteina de fusion terapeutica que comprende un dominio naglu y una porcion de objetivo lisosomal.
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
CO6362052A2 (es) Antagonistas de los receptores tipo toll 3.
ECSP088591A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
BRPI0613770A2 (pt) anticorpos anti-cd26 e métodos de uso destes
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
BR112015005389A2 (pt) composições e sistemas para conferir resistência a doença em plantas e métodos de uso das mesmas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal